WO2002060925A1 - Methode de production d'antithrombine iii latente - Google Patents

Methode de production d'antithrombine iii latente Download PDF

Info

Publication number
WO2002060925A1
WO2002060925A1 PCT/US2002/002082 US0202082W WO02060925A1 WO 2002060925 A1 WO2002060925 A1 WO 2002060925A1 US 0202082 W US0202082 W US 0202082W WO 02060925 A1 WO02060925 A1 WO 02060925A1
Authority
WO
WIPO (PCT)
Prior art keywords
antithrombin iii
buffer
native
atiii
latent
Prior art date
Application number
PCT/US2002/002082
Other languages
English (en)
Inventor
Kimberly Bishop
Michael L. Hayes
Julie S. Pollock
Scott Van Patten
Original Assignee
Genzymes Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzymes Corporation filed Critical Genzymes Corporation
Publication of WO2002060925A1 publication Critical patent/WO2002060925A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III

Definitions

  • the present invention relates to novel methods of producing a latent form of antithrombin III (ATIII). More particularly, the present invention relates to a method of producing a latent form of ATIII without the formation of polymers. Additionally, the present invention relates to a method of producing a latent form of ATIII with an increased level of conversion from the native form to the latent form.
  • ATIII antithrombin III
  • ATIII a member of the serpin family of proteins, is a single chain glycoprotein that functions as an inhibitor of thrombin and other factors in the blood coagulation cascade.
  • ATIII can be found in many organisms which produce the protein in nature, in particular, humans, bovines, and goats. It is synthesized primarily in the liver with a signal peptide of 32 amino acids necessary for its intracellular transport through the endoplasmic reticulum; the peptide is then cleaved prior to secretion. Mourey et al., Biochimi ⁇ 72:599-608 (1990). ATIII is present in serum levels of 12.5 mg/dL.
  • ATIII may be found in the serum of individuals who have either a hereditary deficiency of ATIII or an acquired deficiency, which can result from a number of pathologic conditions. It has a molecular weight of approximately 58,000 daltons, containing 432 amino acids and has a carbohydrate content of about 15%.
  • the protein has three disulfide bridges connecting Cys8-128, Cys21- 95 and Cys247-430 and four potential N-linked glycosylation sites located at Asn 96, Asn 135, Asn 155 and Asn 192.
  • ATIII is also produced transgenically.
  • ATIII currently is produced as recombinant human antithrombin III (r-hATIII) in the milk of transgenic goats.
  • Transgenic r-hATIII is a highly purified, well characterized recombinant glycoprotein.
  • a detailed biochemical comparison of ATIII isolated from the milk of transgenic goats and ATIII isolated from human plasma has been carried out.
  • Transgenic ATIII is comparable to human plasma ATIII with respect to: specific activity, purity, degree of oxidation, amount of aggregates, primary sequence, secondary, and tertiary structure.
  • human plasma ATIII is glycosylated with biantennary complex structures that are predominantly disialylated at all four sites.
  • Transgenic ATIII also contains biantennary complex structures at Asn 96, 135 and 192. However, these biantennary oligosaccharides are fucosuylated and are a mix of mono-and disialylated structures. Substitution of N-acetylgalactosamine for galactose is also observed on some of these complex glycans as is substitution of N-glycolyl neuraminic acid for N-acetylneuraminic acid.
  • Human plasma ATIII does not contain either N-glycolyl neuraminic acid or N-acetylgalactosamine on its oligosaccharide chains. Oligomannose and hybrid oligosaccharides are present at Asn 155 of the transgenic ATIII.
  • This difference in glycosylation may account for the slight difference observed in heparin affinity between human plasma ATIII and transgenic ATIII with transgenic ATIII having a slightly higher overall heparin affinity.
  • the increased heparin affinity of transgenic ATIII does not affect the inhibition of thrombin in the presence of excess heparin.
  • S-ATIII the active native intact form of ATIII is designated the S (stressed) form (S-ATIII).
  • S-ATIII forms a tight binding complex with thrombin (markedly enhanced by the presence of heparin) and other enzymes (not all serpins have heparin affinity).
  • S-ATIII, as well as other serpins, share a common three dimensional structure which can undergo large conformational changes under certain circumstances. (Carrell, R. et al., Structural Mobility of Antithrombin and its Modulation by Heparin, Thromb. Haemost, 78, 516-519 (1997)).
  • Serpins contain a reactive center loop, for example, that is directly involved in the inhibition of their target proteases, which in the case of ATIII includes thrombin.
  • the loop on the serpin is cleaved by the protease, resulting in a conformational change in the serpin that traps the protease, thereby rendering it inactive.
  • This trapping involves the stable insertion of half of the cleaved reactive center loop into a beta sheet within the structure of the serpin and results in a stable protease-serpin complex (e.g., thrombin-ATIII or TAT complexes).
  • S-ATIII can be cleaved to another native form of ATIII, the relaxed (R)- conformation (R-ATIII), by a variety of enzymes, including thrombin. Evans et al., Biochemistry, 31 :12629-12642 (1992). For example, it has been thought that thrombin binds to a reactive C-terminal loop of ATIII and the resultant complex slowly dissociates releasing thrombin and cleaving off the C-terminal loop of inactive ATIII, resulting in R-ATIII. The cleavage occurs spontaneously, even at cold temperatures. R-ATIII is unable to bind thrombin and has a conformation that is quite different from that of S-ATIII. Certain non-target proteases, such as elastase, can also cleave the loop. However, these proteases do not remain bound to the serpin, resulting in a free, cleaved serpin.
  • Some serpins can have the loop inserted into the beta sheet without cleavage by using partial denaturing conditions that destabilize the beta sheet.
  • This form of the protein is called the latent form of ATIII (L-ATIII) and, like the cleaved, native form, is both stable and inactive as a protease inhibitor.
  • Native ATIII may be converted to L-ATIII using mild denaturing conditions which cause a conformational change in the native protein resulting in the insertion of an external loop into a beta sheet in the body of the protein. This treatment leaves the protein intact in terms of amino acid sequence and disulfide bonding.
  • ATIII antiangiogenic form of ATIII. It was observed in human tumor cell culture supernatant that was, in fact, shown to be bovine ATIII cleaved on its reactive center loop near the normal thrombin cleavage site. This was presumed to be the result of the culture tumor cells producing an as yet unidentified protease which cleaved bovine ATIII present in the serum used to culture cells. A group of experiments were conducted to more clearly define the nature of this antiangiogenic form of ATIII.
  • bovine and human ATIII were purified from plasma and then cleaved on the reactive site loop in vitro using elastase. These preparations were demonstrated to be antiangiogenic using the chick chorioallantoic membrane assay.
  • the elastase-cleaved preparations of ATIII (EC-ATI 11) were also shown to be inhibitors of both bovine capillary endothelial (BCE) cell proliferation and tumor growth in SK-NAS human neuroblastoma model.
  • BCE bovine capillary endothelial
  • EC-ATI 11 (relaxed) prepared using recombinant human ATIII (r-hATIII; transgenic) is active in a tumor inhibition assay.
  • L-ATIII Due to the structural similarity of the L-ATIII to EC-ATI 11 (each with all or part of the reactive center loop inserted into the beta sheet), it was theorized that L- ATIII might also be active in this context. Preparations of ATIII using denaturants that had been shown to result in formation of L-ATIII were made. These preparations proved to inhibit endothelial cell proliferation and tumor growth. Purified preparations of L-ATIII were subsequently made which also were shown to inhibit tumor growth. As a result, administration of L-ATIII as a cancer treatment or as tumor suppressant is currently undergoing clinical trials- It was later shown, however, that these preparations contained primarily polymers of ATIII. Consequently, while L-ATIII has shown promise as a tumor inhibitor there are currently two major problems associated with producing L-ATIII on a large scale: (1) the formation of ATIII polymers during the conversion; and (2) the incomplete conversion from native to latent form.
  • the present invention in one aspect, provides a method of preparing latent antithrombin III comprising: preparing a solution comprising native antithrombin III with a buffer, wherein said buffer contains at least one citrate and at least one glycerol; and heating the solution. The step of heating converts the native antithrombin III into latent antithrombin III.
  • Fig. 2 shows the results of a BCE proliferation assay for cleaved and latent ATIII.
  • Fig. 3 shows the tumor volume for cleaved and latent ATIII.
  • the invention in one aspect, provides a method of preparing latent ATIII comprising: preparing a solution comprising native ATIII and a buffer, wherein said buffer contains at least one citrate and at least one glycerol; and heating the solution.
  • the step of heating converts the native ATIII into latent ATIII.
  • the latent form of ATIII is ATIII which has been mildly denatured such that it has a heparin affinity and has lost its ability to inhibit thrombin.
  • a buffer containing citrate such as sodium citrate
  • glycerol in the buffer reduced the formation of ATIII polymers, an unexpected property. It is believed that the combination of citrate and glycerol, at optimal concentrations, enhanced the conversion of native ATIII to L-ATIII.
  • the methods of the invention are well suited to both laboratory and large scale production of L-ATIII.
  • the source material, i.e., native ATIII, for the preparation of L-ATIII may be derived from any organism which produces the protein in nature, in particular, humans, bovines, and goats.
  • ATIII can be isolated from body fluids such as serum, ascites, and urine.
  • ATIII may also be synthesized chemically or biologically, such as by cell culture or recombinant technology, or produced transgenically.
  • particular portions and conformations of ATIII that may also be used in the methods of the invention can be isolated from natural sources, produced transgenically, or can be chemically or biologically synthesized, such as by guanidine treatment or in vitro cleavage of ATIII.
  • recombinant techniques known in the art include, but are not limited to, gene amplification from DNA using polymerase chain reaction (PCR), gene amplification from RNA using reverse transcriptase PCR and NASBA (nucleic acid sequence based amplifications).
  • PCR polymerase chain reaction
  • RNA reverse transcriptase PCR
  • NASBA nucleic acid sequence based amplifications
  • recombinant L-ATIII denoted r-L-ATIII
  • r-hATIII may be prepared from recombinant human antithrombin III (r- hATIII).
  • the r-hATIII may produced by any methods known in the art including, for example, in the milk of transgenic goats.
  • the native ATIII may be purified before addition of the buffer and subsequent conversion to the latent form or after addition of the buffer and/or conversion, i.e., purification of the L-ATIII. Furthermore, it is within the practice of the invention to not purify the native or L- ATIII.
  • the native ATIII is added to a solution with a buffer that contains at least one citrate and at least one glycerol.
  • the citrate surprisingly aids in the conversion of native ATIII to L-ATIII.
  • the citrate is present in the buffer in an amount ranging from, for example, about 10 to about 400 mM, and such as from about 40 to about 300 mM. More preferably, the citrate is present in the buffer in an amount of about 250mM.
  • the range of ATIII to buffer for example, is from greater than 0 to about 50mg ATIII/mL of buffer, such as from about 5 to about 10 mg/mL.
  • Any citrate may be used in the practice of the invention including, but not limited to, sodium citrate and potassium citrate.
  • Glycerol provides the surprising property of reducing the number of ATIII polymers that are formed during the conversion process.
  • glycerol for example, may be present in an amount ranging from about 1 to about 40% of the total weight of the buffer, such as from about 10 to about 30% of the total weight of the buffer. In another embodiment, glycerol is present at an amount of about 20% of the total weight of the buffer.
  • One of skill in the art may determine the amount of glycerol desired depending on the application envisaged.
  • the buffer may also contain sodium chloride, or other salts, acids, and/or bases that may adjust the pH of the buffer and/or solution.
  • the pH of the buffer ranges from about 3 to about 7, such as from about 4 to about 6. Not to be limited as to theory, in some cases a lower pH appears to promote faster conversion from the native to latent forms of ATIII.
  • native ATIII may be converted to L-ATIII using mild denaturing conditions. This may cause a conformational change in the native protein, resulting in the insertion of an external loop into a beta sheet in the body of the protein. This treatment leaves the protein intact in terms of amino acid sequence and disulfide bonding. Any denaturing process that converts ATIII from the native to the latent form may be within the practice of the invention. Heating, for example, may be used to drive the conversion.
  • any temperature that results in conversion from native ATIII to L-ATIII is within the practice of the invention.
  • the temperature ranges, for example from about 50°C to about 60°C, however the temperature may be optimized based on the application envisaged. For example, at a temperature above 52°C, one may observe more polymer formation, while at lower temperatures, a slower conversion from the native to the latent forms may be observed.
  • the amount of time spent heating will also vary depending on the application envisaged and the temperature chosen.
  • the temperature may be cycled throughout the preparation process. It is well within the ordinary skill in the art to determine the amount of heating necessary to reach the end products desired. In one embodiment, the solution is heated for about 4 days and in another embodiment for about 6 days.
  • a composition or alter the reaction conditions to reduce oxidation of the ATIII Prior to heating, one may also add a composition or alter the reaction conditions to reduce oxidation of the ATIII. For example, an overlay of nitrogen may be added to the reaction conditions and/or a methione, such as L-methione may be added to the solution.
  • ATIII is diafiltered into the buffer.
  • the subsequent heating allows the ATIII to undergo a controlled conformational change to the lower energy "latent" conformer.
  • the process may be optimized by the addition of a buffer containing a citrate, glycerol, and methionine in order to maximize the amount of ATIII converted to the latent form and minimize the formation of product variants caused by the two identified major routes of degradation: multimer formation (aggregation) and methionine oxidation.
  • At least about 50% of the native ATIII is converted to L- ATIII. such as at least about 60% and such as about 80%. In one embodiment, about 97% L-ATIII is produced with 0% native ATIII and less than about 5% polymer.
  • the resulting L-ATIII is heated to kill any virus in the product and/or to convert any remaining native ATIII to L-ATIII. In one embodiment, the L-ATIII is heated to about 60°C.
  • Purified r-hATIII (Methyl-Eluate) is concentrated and diafiltered into a buffer, filtered into a sterilized vessel through a sterilizing-grade 0.2 urn membrane filter, and then heated at 50+ 1 °C for 5 days.
  • the stabilizing buffer contains approximately 250 mM sodium citrate, 20% glycerol and 20 mM L-methionine, at a pH 6.0. No polymers were formed and conversion to latent was nearly complete (80%) after about 100 hours.
  • the purified r-L-ATIII may be concentrated and diafiltered into a formulation buffer to produce the bulk drug substance.
  • a schematic depiction of an example of an r-hATIII purification process and the conversion to r-L-ATIII is shown in Fig. 1.
  • the source material may be prepared from frozen milk produced by transgenic goats expressing the human ATIII gene. The milk is then thawed, clarified by tangential flow filtration and the ATIII-containing clarified permeate purified for example through a Heparin-column chromatography step. The eluted material is transferred to a dedicated downstream-processing area and is diafiltered to reduce conductivity and processed through an anion-exchange chromatography step.
  • the anion-exchange eluted material is adjusted to high ionic strength with sodium citrate and processed through the final purification step, hydrophobic interaction chromatography.
  • the process results in a highly-purified product meeting specifications for general purity, (SDS-PAGE, and reversed phase HPLC), for immunogenic protein impurities (protein impurity ELISA)and goat DNA.
  • the inventors have optimized the conversion of r-hATIII to both EC-ATI 11 and L-ATIII. Preparations of these two forms have been assayed using the BCE proliferation assay (Fig. 2) and the Lewis lung carcinoma mouse model (Fig. 3). These assays were done with identical replicate samples of a given preparation of each form, and the identity of all samples was blended until final results were obtained. Samples of BSA and untreated r-hATIII were included as negative controls. Based on this data, there is no significant difference between the two forms in terms of their anti-angiogenic or anti-tumor activity.

Abstract

L'invention concerne une méthode de production d'antithrombine III (ATIII) latente consistant à préparer une solution qui comprend une ATIII native et un tampon, ledit tampon contenant au moins un citrate et au moins un glycérol; et à chauffer ladite solution. La phase de chauffage permet de convertir l'ATIII native en ATIII latente. La méthode de l'invention permet d'obtenir une conversion plus complète de l'ATIII native en une forme latente. L'invention également la formation d'impuretés telles que des polymères ATIII et des produits d'oxydation.
PCT/US2002/002082 2001-01-30 2002-01-25 Methode de production d'antithrombine iii latente WO2002060925A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26467401P 2001-01-30 2001-01-30
US60/264,674 2001-01-30

Publications (1)

Publication Number Publication Date
WO2002060925A1 true WO2002060925A1 (fr) 2002-08-08

Family

ID=23007112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/002082 WO2002060925A1 (fr) 2001-01-30 2002-01-25 Methode de production d'antithrombine iii latente

Country Status (1)

Country Link
WO (1) WO2002060925A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056870A2 (fr) * 2002-12-19 2004-07-08 Octapharma Ag Procede de separation
US7553413B2 (en) 2005-02-07 2009-06-30 Hanuman Llc Plasma concentrator device
US7694828B2 (en) 2005-04-27 2010-04-13 Biomet Manufacturing Corp. Method and apparatus for producing autologous clotting components
US8801586B2 (en) 2008-02-29 2014-08-12 Biomet Biologics, Llc System and process for separating a material
US8950586B2 (en) 2002-05-03 2015-02-10 Hanuman Llc Methods and apparatus for isolating platelets from blood
US8992862B2 (en) 2009-04-03 2015-03-31 Biomet Biologics, Llc All-in-one means of separating blood components
US9011800B2 (en) 2009-07-16 2015-04-21 Biomet Biologics, Llc Method and apparatus for separating biological materials
US9114334B2 (en) 2002-05-24 2015-08-25 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US9138664B2 (en) 2007-04-12 2015-09-22 Biomet Biologics, Llc Buoy fractionation system
US9239276B2 (en) 2011-04-19 2016-01-19 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US9533090B2 (en) 2010-04-12 2017-01-03 Biomet Biologics, Llc Method and apparatus for separating a material
US9550028B2 (en) 2014-05-06 2017-01-24 Biomet Biologics, LLC. Single step desiccating bead-in-syringe concentrating device
US9556243B2 (en) 2013-03-15 2017-01-31 Biomet Biologies, LLC Methods for making cytokine compositions from tissues using non-centrifugal methods
US9642956B2 (en) 2012-08-27 2017-05-09 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US9649579B2 (en) 2007-04-12 2017-05-16 Hanuman Llc Buoy suspension fractionation system
US9701728B2 (en) 2008-02-27 2017-07-11 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US9897589B2 (en) 2002-05-24 2018-02-20 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US10183042B2 (en) 2002-05-24 2019-01-22 Biomet Manufacturing, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US10576130B2 (en) 2013-03-15 2020-03-03 Biomet Manufacturing, Llc Treatment of collagen defects using protein solutions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CARRELL ET AL.: "Biological implications of a 3 angstrom structure of dimeric antithrombin structure", STRUCTURE, vol. 2, no. 4, 1994, pages 257 - 270, XP002950393 *
KARLSSON ET AL.: "Separation of native and latent forms of human antithrombin by hydrophobic interaction high-performance liquid chromatography", PROT. EXP. & PURIF., vol. 21, 2001, pages 149 - 155, XP002950396 *
LARSSON ET AL.: "A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity", J. BIOL. CHEM., vol. 276, no. 15, 13 April 2001 (2001-04-13), pages 11996 - 12002, XP002950397 *
LOMAS ET AL.: "Preparation and characterization of latent alpha1-antitrypsin", J. BIOL. CHEM., vol. 270, no. 10, 10 March 1995 (1995-03-10), pages 5282 - 5288, XP002950394 *
O'REILLY ET AL.: "Antiangiogenic activity of the cleaved conformation of the serpin antithrombin", SCIENCE, vol. 285, 17 September 1999 (1999-09-17), pages 1926 - 1928, XP002950395 *
WARDELL ET AL.: "Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1", BIOCHEMISTRY, vol. 36, no. 42, October 1997 (1997-10-01), pages 13133 - 13142, XP000916333 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8950586B2 (en) 2002-05-03 2015-02-10 Hanuman Llc Methods and apparatus for isolating platelets from blood
US10183042B2 (en) 2002-05-24 2019-01-22 Biomet Manufacturing, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US10393728B2 (en) 2002-05-24 2019-08-27 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US9897589B2 (en) 2002-05-24 2018-02-20 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US9114334B2 (en) 2002-05-24 2015-08-25 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
WO2004056870A3 (fr) * 2002-12-19 2004-10-14 Octapharma Ag Procede de separation
WO2004056870A2 (fr) * 2002-12-19 2004-07-08 Octapharma Ag Procede de separation
US7553413B2 (en) 2005-02-07 2009-06-30 Hanuman Llc Plasma concentrator device
US7694828B2 (en) 2005-04-27 2010-04-13 Biomet Manufacturing Corp. Method and apparatus for producing autologous clotting components
US9011687B2 (en) 2005-04-27 2015-04-21 Biomet Biologics, Llc Method and apparatus for producing autologous clotting components
US9138664B2 (en) 2007-04-12 2015-09-22 Biomet Biologics, Llc Buoy fractionation system
US9649579B2 (en) 2007-04-12 2017-05-16 Hanuman Llc Buoy suspension fractionation system
US11725031B2 (en) 2008-02-27 2023-08-15 Biomet Manufacturing, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US9701728B2 (en) 2008-02-27 2017-07-11 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US10400017B2 (en) 2008-02-27 2019-09-03 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US9719063B2 (en) 2008-02-29 2017-08-01 Biomet Biologics, Llc System and process for separating a material
US8801586B2 (en) 2008-02-29 2014-08-12 Biomet Biologics, Llc System and process for separating a material
US8992862B2 (en) 2009-04-03 2015-03-31 Biomet Biologics, Llc All-in-one means of separating blood components
US9011800B2 (en) 2009-07-16 2015-04-21 Biomet Biologics, Llc Method and apparatus for separating biological materials
US9533090B2 (en) 2010-04-12 2017-01-03 Biomet Biologics, Llc Method and apparatus for separating a material
US9239276B2 (en) 2011-04-19 2016-01-19 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US9642956B2 (en) 2012-08-27 2017-05-09 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US9556243B2 (en) 2013-03-15 2017-01-31 Biomet Biologies, LLC Methods for making cytokine compositions from tissues using non-centrifugal methods
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US10441634B2 (en) 2013-03-15 2019-10-15 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US10576130B2 (en) 2013-03-15 2020-03-03 Biomet Manufacturing, Llc Treatment of collagen defects using protein solutions
US11957733B2 (en) 2013-03-15 2024-04-16 Biomet Manufacturing, Llc Treatment of collagen defects using protein solutions
US9550028B2 (en) 2014-05-06 2017-01-24 Biomet Biologics, LLC. Single step desiccating bead-in-syringe concentrating device

Similar Documents

Publication Publication Date Title
WO2002060925A1 (fr) Methode de production d'antithrombine iii latente
CA2192683C (fr) Filtration
TWI394534B (zh) 萃取存在於乳汁中一或多種蛋白質之方法
Lambeir et al. A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma
US20020090711A1 (en) Process for preparing latent antithrombin III
EP1519944B1 (fr) Procedes de preparation du fibrinogene
US4379085A (en) Heat stabilization of plasma proteins
Björk et al. Decreased affinity of recombinant antithrombin for heparin due to increased glycosylation
KR20030057545A (ko) 잠복형 안티트롬빈 ｉｉｉ의 제조방법
US8076462B2 (en) Method for producing antithrombin composition
JP2532535B2 (ja) 組織タンパクｐｐ４含有医薬
US5777081A (en) Process for producing an inter-alpha-trypsin inhibitor concentrate for therapeutic use and concentrate thus obtained
KR100685448B1 (ko) 지혈 활성 ｖＷＦ-함유 제조물 및 이의 제조 방법
US20130085111A1 (en) Production of human c1 inhibitor in human cells
EP0823476B1 (fr) Procédé d'activation de la prothrombine en thrombine
CA1340236C (fr) Methode pour preparer un inhibiteur d'alpha-1-proteinase hautement purifie
Boswell et al. Reactive site of α1-antitrypsin is C-terminal, not N-terminal
WO2000000516A1 (fr) Nouveau peptide lie par une chaine de sucres et similaire a la thrombomoduline
JPH1080281A (ja) 新規蛋白質及びその製造方法
JPH05208999A (ja) セリンプロテアーゼインヒビターおよびこれを含有する医薬組成物
JPH04502324A (ja) 純粋なｉ因子蛋白質および該蛋白質の製造方法
JP2551424B2 (ja) ＴＧＦ−β制御糖タンパク質サブユニツト
JPS62221636A (ja) Ｂ型肝炎ウイルス抗原蛋白の可溶化方法
RU2326689C1 (ru) Способ получения концентрата viii фактора свертывания крови человека и продукт его содержащий
RU2026553C1 (ru) Способ выделения c3 - компонента комплемента человека

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP